HBC Immunology shares promising results for prostate cancer co-therapy
There are around 55,100 new prostate cancer cases in the UK every year
Read More
Tag: Xtandi
Astellas’ Xtandi bags NICE approval in prostate cancer
Oral androgen receptor signalling inhibitor now approved to treat metastatic hormone-sensitive prostate cancer
Read More
Astellas’ Xtandi bags additional MHRA approval in prostate cancer
Once-daily oral Xtandi approved for the treatment of adult men with metastatic hormone-sensitive prostate cancer
Read More
Priority Review awarded to Xtandi for prostate cancer
Back in February, the companies revealed results from the Phase III ARCHES trial in men with mHSPC.
Read More
Xtandi successful in prostate cancer Phase III trial
Pfizer and Astellas have unveiled results from the Phase III ARCHES trial in men with metastatic hormone-sensitive prostate cancer (HSPC), showing that Xtandi significantly improved radiographic progression-free survival, paving the way for an application to expand the drug’s use.
Read More
Pfizer/Astellas’ Xtandi cuts risk of prostate cancer spread
Adding Pfizer and Astellas Pharma’s Xtandi to hormone therapy significantly cut the risk of prostate cancer spreading compared to hormone therapy alone, trial findings show.
Read More
Pfizer swoops in to grap Medivation for $14bn
Following weeks of speculation Pfizer has stepped forward with a $14-billion bid for Medivation, beating Sanofi and other suitors to the finish line in a move designed to boost its oncology portfolio.
Read More
Merck joins the pack circling Medivation
Merck & Co is reportedly the latest pharma to consider snapping up US cancer biotech Medivation.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
